Cubist Achieves Top Biotech Ranking in Globe 100 List
News May 20, 2013
For the fifth consecutive year, Cubist Pharmaceuticals, Inc. has been named to the Globe 100 annual list, the Boston Globe’s annual ranking of the 100 top-performing public companies headquartered in Massachusetts. Cubist was ranked number six overall and was named the top performing biotech company. The 2013 list was published in the Globe 100 Magazine in the Sunday Boston Globe on May 19.
Cubist, a leading biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment, is headquartered in Lexington, Mass. and employs approximately 780 people. Total net revenues in 2012 grew 23 percent to $926.4 million compared to $754.0 million in 2011.
"Inclusion in the Globe 100 represents an achievement our employees and shareholders should be very proud of as it acknowledges the value of our efforts to deliver breakthrough treatments for patients in an acute care setting,” said Michael Bonney, chief executive officer of Cubist. “As outlined in 2012, our Building Blocks of Growth strategic initiative provides a terrific roadmap for us to achieve continued growth in the Commonwealth and improve treatment options in areas of high unmet medical need. We look forward to many more years as a Globe 100 company.”
Based on a composite score derived from financial data for the four quarters ending December 31, 2012, Cubist was ranked 6th among Massachusetts-based companies whose stock is publicly traded on NASDAQ, New York Stock Exchange or American Stock Exchange. Cubist was ranked 1st among top performing biotechnology companies.
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Investigational Drug for Melanoma Shows Promise in Early-Stage StudyNews
An investigational compound designed to block a hyperactive cell growth signal in advanced melanoma and other cancers has shown some promise in an early-stage clinical trial researchers have reported.READ MORE
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018